⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for dna hypomethylating agent

Every month we try and update this database with for dna hypomethylating agent cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)NCT01261312
MDS
CMML
AML
SGI-110
SGI-110
18 Years - Astex Pharmaceuticals, Inc.
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal CarcinomasNCT03233724
Carcinoma, Non-...
Lung Cancer
Non-Small Cell ...
Carcinoma, Esop...
Malignant Pleur...
Decitabine (DAC...
Tetrahydrouridi...
Pembrolizumab
18 Years - 99 YearsNational Institutes of Health Clinical Center (CC)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: